Can our institution use Copernicus Group IRB (CGIRB) to review some of our research studies, while maintaining local oversight for other studies?
Yes. After discussions between CGIRB and your institutional representatives, a program can be customized to fit the specific needs of your institution. This may allow for a subset of studies to be reviewed by CGIRB (ie, Industry Sponsored studies) or may allow CGIRB to review research at specific sites within your institution (ie, your outpatient research facility).
For what type of research does CGIRB have experience in providing IRB oversight?
CGIRB has experience in the review of the following:
- FDA and OHRP Regulated Studies
- Phase I-IV Drug Studies in all therapeutic areas
- Device Studies
- Biologic Studies
- Observational/Registry Studies
- Social-Behavioral Studies
Would using an external IRB require adding additional institutional administrative staff?
Partnering with CGIRB should reduce the workload of your existing IRB. However, an individual at your institution will need to be designated to work with CGIRB to assist with issues such as tracking of submissions, review of periodic reports, investigator questions, and payment of invoices. In current models, this role is usually held by an individual who is involved with or at least familiar with your existing IRB process.
Can we come to visit CGIRB to see the facility and look at SOPs?
In order to best protect human subjects at your institution we want to build an honest working relationship with open communication every step along the way. To foster this culture, we encourage representatives from your institution to visit our facility in North Carolina. During your visit we would be able to provide a tour of our facility, let you review our SOPs and Policies, and introduce you to our staff and board members to give you an idea of the experience and expertise of CGIRB.
How would CGIRB consider the local concerns of our institution’s subject population?
Local considerations regarding the acceptance of research within the potential subject population is of importance for every review. CGIRB may obtain this information in a variety of ways, such as consultation with your institutional officials and via the Investigator Site Questionnaire, among others. (see forms)
Our institution does not have an Federalwide Assurance (FWA) filed with The Office of Human Research Protection (OHRP). Could we still use the ethical review services of CGIRB?
Yes. CGIRB can provide ethical review and oversight for institutions who do not hold an FWA as well as for institutions who currently have an FWA filed with OHRP. In each case a written agreement between the institution and CGIRB will be executed clearly stating the type of service being delegated to CGIRB. This agreement will also state that CGIRB will follow their own internal SOPs for any review being done for the institution and it’s investigators.
In addition to the written agreement mentioned above, the following will be required prior to submitting proposals to CGIRB.
If you have an FWA:
- You must update your FWA to include CGIRB (Registration #IRB00001313) and submit to OHRP
- You must execute an IRB Authorization Agreement with CGIRB (see forms)
If you do not currently have an FWA filed with OHRP:
- You must complete documentation to waive jurisdiction for IRB review. This must be signed by the IRB Chairperson, Institutional Official or other authorized individual. For your convenience, CGIRB has an IRB Authorization Agreement form on our website.
How much time would it take to set up a human research protection partnership between CGIRB and our institution?
As you might imagine, the answer to this question will vary. A conservative estimate would be to allow 3-6 months from initial discussions to the first review conducted by CGIRB. Variables that may impact this timeline would be:
- Level of acceptance from institutional officials for the transfer of IRB obligations
- Availability of a liaison to customize your work flow plan
- Education and training of investigators on the new submission process
What are some of the benefits we could realize by partnering with CGIRB for the support of our human research protection program?
- Excellent Research Oversight
- Decrease Local IRB Workload
- Multiple Meetings per Week to Better Meet Timelines
- Partnership with an IRB who has received Full AAHRPP Accreditation of its Human Research Protection Program
- Adaptable Processes
- Large and Knowledgeable CGIRB Support Staff
- Easy Transfer Process
- Education and Training Resources
Does CGIRB apply signatures to approval documents?
Based on current regulatory requirements and industry standards, CGIRB does not apply signatures to approval documents and other routine communications provided to clients and to investigator sites. (See CGIRB’s Statement of Signature Requirement).
How often does Copernicus Group IRB hold Board meetings
CGIRB Board meetings are held every Tuesday and Thursday with the exception of Thanksgiving week and Christmas week. (See Schedule)
If we are interested in having a protocol and Subject Information and Consent Form reviewed, when does CGIRB need the material?
We have a schedule of submission dates that must be met in order to assure CGIRB Board review at a specific scheduled meeting. Generally, the submission deadline is by 5:00 PM, one week before the scheduled Board meeting you desire. Please contact us for additional information regarding the CGIRB meeting schedule. (See Schedule)
How quickly does CGIRB notify researchers of the Board review decisions?
Approval documents are sent to the Principal Investigator within 2-3 business days of an unconditional approval decision. Whenever possible, CGIRB sends decisions within 3 business days of the review meeting. In cases where there is a condition placed on approval, the condition must be met prior to processing the unconditional approval documents.
What is CGIRB’s policy for reporting IND Safety reports?
The majority of IND Safety Reports, Suspected Unexpected Serious Adverse Reaction (SUSAR) Reports, Council for International Organizations of Medical Sciences (CIOMS) Reports, and MedWatch Reports (“Reports”) are unlikely to meet reporting requirements under CGIRB reporting guidelines. Reports that must be reported are those reports that indicate a new or increased risk of harm to subjects or others. Generally, to be reportable, such an event should be previously unknown to the IRB and requires an action taken to minimize the risk to other subjects, such as a change to the protocol or additional disclosure of risk information in the consent document.
If there is an agreement that the sponsor report unanticipated problems directly to CGIRB on the behalf of the PI, that is the only report that needs to be submitted to CGIRB. If there is no such agreement in place, the PI is required to submit reports to CGIRB, if they are determined to be reportable unanticipated problems.
Submit the report with the completed CGIRB Promptly Reportable Information Form within 5 business days of your receipt.
What is CGIRB’s policy for reporting Unanticipated Problems (UPs) other than IND Safety reports?
A UP event is reportable if it meets all of the following:
- related or possibly related to the research
- unexpected in terms of its nature, severity or frequency
- suggests that the research places subjects or others at a new or increased risk of harm
Generally, to be reportable, an event should be previously unknown to the IRB and require some action to be taken to minimize the risk to subjects or others, such as a safety-related change to the protocol or additional disclosure of risk information in the consent document or investigator’s brochure.
Under the above definition, many adverse events will not meet CGIRB reporting requirements.
Submit reportable UPs on the Promptly Reportable Information Form within 5 business days of the site’s awareness.
You will receive an acknowledgement for submissions that meet the CGIRB reporting requirements.
What are the “rights” of a research subject?
If you decide to be in a research study, you should carefully read and discuss the CGIRB-approved Subject Information and Consent Form with the study staff and study doctor before having any procedures done. Any questions you have should be answered. The decision of whether to take part in the study is completely voluntary. You and only you should make this decision. As a research subject, you have a right to information about the study procedures, study drug, risks and benefits of the study, alternative treatment, confidentiality, and any payment that may be provided for taking part. If you do not understand why something is being done during the study… ask. If you decide to take part in a study, you also have a right to withdraw from the study at any time.
What do we mean when we discuss Quality Assurance in research?
Human subject research is governed by numerous regulations and guidances. Additionally, most sponsors, CROs, SMOs, investigator sites, institutions, and IRBs have standard operating procedures (SOPs) in place to govern activities associated with the conduct of clinical research. All of these regulations, guidelines, SOPs, the IRB-approved protocol, and other procedural documents serve as standards against which compliance may be assessed. Quality assurance auditors are employed at various stages of the research and development process to assess compliance with applicable standards. The purpose of most clinical quality assurance audits is to verify, through interviews and documentation reviews, the following:
- That the rights and welfare of the human research subjects are and have been protected
- That the research study is being conducted in accordance with the IRB-approved protocol and in compliance with applicable regulations, guidelines, SOPs, and other written standards
- That the investigator is administering the investigational product only to subjects under the investigator’s personal supervision or under the supervision of a sub-investigator responsible to the investigator, and that the investigator is maintaining accountability for the investigational product
- That the data, derived from source documentation, are verifiable
Because FDA and OHRP encourage research entities to conduct internal quality assurance activities in an effort to provide continuous quality improvement, audit reports are not routinely requested during regulatory inspections. Therefore, documentation associated with quality assurance audits does not have to be maintained and retained with the study documentation. It is preferable for audit documentation to be maintained in a separate location from research study files
What is HIPAA?
“HIPAA” stands for the Health Insurance Portability and Accountability Act of 1996. This regulation includes “the Privacy Rule”, which outlines the standards for privacy of individually identifiable health information. The specific regulations for HIPAA are in Title 45 CFR Parts 160 and 164.
What is a review preparatory to research?
This is a specific term related to the review of a potential subject’s PHI [private health information or individually identifiable health information] in order to prepare a research protocol or for similar purposes, such as to determine whether the person might be eligible for participation in a research study. By following the requirements for a review preparatory to research, you will comply with HIPAA as you seek to identify potential subjects whose PHI will not be disclosed to third parties without the subject’s prior authorization. Note that this method must not be used if such PHI will be disclosed to a third party to the covered entity.
The requirements for complying with this approach are as follows:
- Notification by the covered entity that the review of PHI is needed in order for the preparation of a research protocol or for similar purposes, such as to determine whether a person might be eligible for participation in a research study.
- Notification that the PHI will be used solely for this review preparatory to research.
- Notification that the PHI is necessary for the purposes of this review.
- Notification that the PHI will not be disclosed to third parties to the covered entity.
Note that CGIRB is not involved in this activity. We only include this information as a service to you.
Does CGIRB have Authorization language incorporated into a Subject Information and Consent Form Template?
Yes, we do. Go to our forms section for the Subject Information and Consent Form and Authorization to Use and Disclose Personal Health Information for Research Template.
Will CGIRB accept submissions of alternative authorization language?
Yes, alternative Authorization language can be submitted to CGIRB for Board review. This language would need to meet the standard that CGIRB has adopted. The CGIRB Checklist for HIPAA Authorization Language can be found on our forms page.
Can a Sponsor/CRO collect PHI regarding a subject who signed the consent to participate section of the Subject Information and Consent Form but inadvertently did not sign the HIPAA authorization section?
If the investigator/site is not a covered entity, then the answer is Yes. HIPAA would not apply to a non-covered entity and therefore authorization is not required.
However, if the investigator/site is a covered entity under the provisions of HIPAA, then written authorization from the subject is required prior to disclosure of the subject’s PHI. The investigator may collect the PHI, since he/she is the covered entity; however, allowing an unaffiliated monitor to view the source documents would constitute an unauthorized disclosure to a third party.
In order to determine if a site is a covered entity, consult the following federal website: http://www.cms.hhs.gov/HIPAAGenInfo/06_AreYouaCoveredEntity.asp
As a Principal Investigator, how do I find out who can be the Legally Authorized Representative for a research subject?
Who can serve as a legally authorized representative (LAR) is determined on a state-by-state basis. When a study requires consent to be provided by an LAR, CGIRB requests that the Principal Investigator (PI) confirm with a regulatory attorney or with the sponsor who may serve as an LAR for their particular state. The Sponsor is responsible for ensuring proper monitoring of investigators under Title 21 Part 312.50 and Title 45 CRF 46.102, which includes confirming that a legally effective consent process was performed. The PI and/or the person obtaining consent should verify that the person signing as LAR has the authority to provide consent on the subject’s behalf; otherwise the consent may not be legally effective.
Is CGIRB a Covered Entity or Business Associate as defined by HIPAA regulations?
After consulting with several industry experts, attorneys, and regulatory officials, it has been determined that independent institutional review boards are NOT covered entities or business associates. As a result of this, it is our policy that we do not enter into business associate agreements.
Q: How can I determine if my organization is a covered entity?
The Health Insurance Portability and Accountability Act of 1996 (HIPAA – The Privacy Rule) applies to any entity that is:
- A health care provider that conducts certain transactions in electronic form (called a “covered health care provider”)
- A health care clearinghouse
- A health plan
An entity that is one or more of these types of entities is referred to as a “covered entity” in the regulations. A decision tool to assist you in deciding whether or not your organization is a covered entity is available at: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/CoveredEntitycharts.pdf
Where can I find more information about race and ethnicity categories?
The FDA has a Final Guidance Document for Collection of Race and Ethnicity Data in Clinical Trials that was released in September 2005. This document is available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126396.pdf
Specific Categories and Definitions are listed on page 12 of this document and are as follows:
The minimum categories for data on race and ethnicity for Federal statistics, program administrative reporting, and civil rights compliance reporting are defined as follows:
- American Indian or Alaska Native. A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.
- Asian. A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.
- Black or African American. A person having origins in any of the black racial groups of Africa. Terms such as “Haitian” or “Negro” can be used in addition to “Black or African American.”
- Hispanic or Latino. A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term, “Spanish origin,” can be used in addition to “Hispanic or Latino.”
- Native Hawaiian or Other Pacific Islander. A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.
- White. A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.
As a Clinical Investigator, what do I need to do to ensure that I am compliant with HIPAA?
(This answer is based on the assumption that the clinical investigator is a covered entity as defined by the regulations.) For your ongoing studies under the approval of CGIRB, your HIPAA Authorization language must be submitted to the Board for review and be approved prior to its use.
In addition, any time you plan to use or disclose PHI [private health information or individually identifiable health information] as a result of your identifying potential subjects prior to their recruitment, you must follow a plan permitted by HIPAA. For example, to identify potential subjects for inclusion in your research protocol, you would likely need to review the patient’s existing health information. If any of this PHI used to identify potential subjects and/or to recruit subjects is disclosed to a third party, such as when it is reviewed by the study monitor, you must either obtain from CGIRB a Request for Waiver/Alteration of Authorization Form (see forms) See other “waiver of authorization” question below.
Lastly, it is also your obligation to be aware of any state and local laws that raise the standards for privacy beyond the HIPAA requirements.
What is a “waiver of authorization” and how do I obtain such a waiver?
With CGIRB Board approval, subject authorization may be waived if you do the following:
- Provide a brief description of the PHI [private health information] for which use or access has been determined to be necessary.
- Inform CGIRB that the research involves no more than a minimal risk to the privacy of the subject, based on, at least, the presence of the following elements:
- An adequate plan to protect the PHI from improper use or disclosure.
- An adequate plan to destroy the identifiers linked to the PHI at the earliest opportunity consistent with the research, unless there is a health or research justification for retaining the identifiers or such retention is otherwise required by law.
- Declare that the PHI will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research study, or for other research for which the use or disclosure of PHI would be permitted by the regulation.
- Declare that the waiver will not adversely affect the rights and welfare of the subject.
- Declare that the research could not practicably be carried out without the waiver.
- Declare that the research could not practicably be conducted without access to and use of the PHI.
Go to our forms section for the CGIRB Request for Waiver/Alteration of Authorization Form. Note that the CGIRB Board must grant this waiver if the waiver request is related to a study approved by CGIRB.